Thank you for your interest in stem cell transplantation for Multiple Sclerosis. Our center is offering Autologous Hematopoietic Cell Transplantation (AHSCT) as a treatment for select patients with multiple sclerosis. We are following the recommendations published by the National MS Society in 2020 and the American Society of Blood and Marrow Transplantation in 2019 to select appropriate patients for AHSCT. This treatment is available to patients with substantial MS disease activity despite treatment with best available MS medications, known as disease modifying therapies (DMTs).

Research has shown that patients with active, inflammatory MS early in their disease course are the most likely to benefit from AHSCT. Age, time since diagnosis, recent disease activity (MRI changes or worsening disability), and level of disability will all be considered when screening a patient for eligibility. Patients who have not had disease activity in the past 3 years, who have not tried disease modifying therapy, or who have other conditions that would put them at significant risk during transplant will not be eligible for AHSCT.

If you think you could be a good fit for AHSCT, please call: (303) 577-6488. We will be happy to pre-screen you over the phone to see if you could be eligible for this treatment, and provide next steps in the screening process if applicable.

Disease modifying therapies (Must fail one or more to be eligible):

  • Interferon beta-1a (Avonex, Rebif)
  • Interferon beta-1b (Betaseron)
  • Glatiramer acetate (Copaxone)
  • Mitoxantrone (Novantrone)
  • Natalizumab (Tysabri)
  • Fingolimod (Gilenya) ()
  • Cladribine (Mavenclad)
  • Siponimod (Mayzent)
  • Mitoxantrone (Novantrone)
  • Ocrelizumab (Ocrevus)
  • Lemtrada (Alemtuzumab)
  • Other immunosuppressive agents